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For an increase in pandemic preparedness and to overcome yearly efforts and costs for 
the production of seasonal influenza vaccines, new approaches for the induction of 
broadly protective and long-lasting immune responses have been developed during the 
past decade. It is critical to understand the evolution of influenza viruses in response to 
Universal Influenza Vaccines. Antibody pressure on conserved domains may increase 
their variability and lead to the rise of escape mutants. Here we used a mouse challenge 
model with a vaccine construct targeting the long alpha helix of hemagglutinin stalk to 
identify alterations in quasispecies composition. The viral ribonucleic acid from lungs 
of vaccinated and non-vaccinated mice was extracted and analyzed using a next 
generation sequencing approach. The viral ribonucleic acid in the supernatant of 
infected Madin Darby Canine kidney cells was used as comparison. The vaccine used 
elicited significant seroconversion and protection against homologous and heterologous 
influenza virus strains in mice. The vaccine not only significantly reduced lung viral 
titers, but also induced a well-known bottleneck effect by decreasing virus diversity. In 
contrast to the classical bottleneck effect, here we showed a significant increase in the 
frequency of viruses with amino acid sequences identical to that of vaccine targeting the 
long alpha helix domain. No emergence of escape mutants in significant quantity was 
detected after vaccination. These findings support the potential of targeting the 
conserved long alpha helix domains and add to the hope of having a potent and safe 
Universal Influenza Vaccine in the near future.  
  





Im Sinne einer besseren Vorbereitung auf die nächste Influenza-Pandemie und um 
jährliche Anstrengungen und Kosten für die Impfstoffproduktion gegen saisonale 
Influenza zu reduzieren, werden seit den letzten etwa zehn Jahren neue Ansätze für die 
Induzierung breiter, schützender und langanhaltender Immunantwort unternommen. Es 
ist dabei entscheidend die Evolution der Influenzaviren in Reaktion auf solche 
Universellen Grippeimpfungen zu verstehen. Der Stress durch Antikörper, die 
weitgehend konservierte Domänen enthalten, könnte zu vermehrter Variabilität und der 
Entstehung von Fluchtmutanten führen. In einem Mausinfektionsversuch mit einem 
Impfstoffkonstrukt, das die lange Alpha-Helix des Hämagglutinin-Stiels angreift, 
wurden die Veränderungen der Quasispezies untersucht. Die virale Ribonukleinsäure 
wurde aus den Lungen von geimpften und nicht geimpften Mäusen extrahiert und mit 
einem Next-Generation-Sequenzierungsverfahren analysiert. Die virale 
Ribonukleinsäure aus dem Überstand von infizierten Nierenzellkulturen wurde als 
Vergleich herangezogen. Der Impfstoff führte in Mäusen zu signifikanter 
Serokonversion und Schutz gegen homologe und heterologe Influenzaviren. Die 
Impfung reduzierte nicht nur den Virustiter in den Lungen sondern induzierte auch den 
bekannten Flaschenhals-Effekt mit einer signifikanten Abnahme der Virusdiversität. Im 
Gegensatz zum klassischen Flaschenhals-Effekt konnte hier eine Zunahme des 
Virusanteils mit der gleichen Aminosäurensequenz wie der verwendete Impfstoff 
gezeigt werden, der die lange Alpha-Helix angreift. Nach der Impfung konnten keine 
Fluchtmutanten in signifikanter Menge gefunden werden. Diese Ergebnisse 
unterstreichen das Potential, die konservierten Regionen der langen Alpha-Helix ins 
Visier zu nehmen und machen Hoffnung auf eine sichere und wirkungsvolle Universelle 










Influenza is a respiratory disease that affects humans throughout the world. About 3 to 5 
million suffer from severe illness and about 250,000 to 500,000 deaths occur due to 
influenza every year (World Health Organization, 2014). Consequences include high 
financial burden due to work time loss, school absenteeism and strain of health systems. 
Furthermore, adding to yearly epidemics which occur usually during winter (World 
Health Organization, 2014), influenza pandemics are possible and have occurred four 
times within the last 100 years (Paules et al., 2017; Shaw et al., 2013). The so called 
Spanish flu pandemic from 1918/19 has caused up to 50 million deaths (Paules et al., 
2017), estimated in various sources, more than World War First (Tucker, 2005). In 1957 
the Asian Pandemic was caused by an H2N2 strain, the 1968 Hong Kong pandemic by 
an H3N2 and the most recent pandemic, in 2009, was caused by an H1N1 and has been 
referred to as Swine Flu pandemic (Paules et al., 2017). Predictions about when the next 
pandemic will strike are hard to make but researchers seem to agree that there will be a 
next pandemic (Barclay, 2017; Wright et al., 2013).  
2.1.2 Clinical picture 
Influenza is a respiratory disease and onset of symptoms is usually very sudden with 
high fevers, coughs, muscle and joint pains with an incubation period of two days 
(World Health Organization, 2014). Super infection with bacteria is possible which can 
cause higher mortality. In seasonal epidemics mortality lies around 0.1% which in 
pandemics can rise to 2.5% (Wright et al., 2013). Morbidity and mortality are highest in 
the old, the very young, pregnant women and immune-compromised persons (World 
Health Organization, 2014). In pandemics young adults can be significantly affected as 







Clinical signs overlap with other respiratory diseases (Dwyer et al., 2006). Therefore, 
diagnosis by clinical signs alone is linked to low reliability and usually laboratory 
testing is needed to confirm influenza virus as causative agent (Chamberlain, 2009). 
Possible laboratory tests include viral culture, antigen detection and nucleic acid testing 
(Paules et al., 2017). There are rapid influenza diagnostic tests available which play an 
important role in clinical settings but reach a sensitivity of only 40% to 70% (Wright et 
al., 2013), and specificity of 90% to 95% (“CDC flu diagnosis clinician guidance,” 
n.d.).  
2.1.4 Therapy 
Non-specific treatment includes medication against fevers and pain medication against 
muscle and joint pains. Targeting influenza virus specifically, there are two different 
approaches available, neuraminidase inhibitors and M2 proton channel blockers (World 
Health Organization, 2014). Both should be administered during the first 48 hours of 
infection to reach the best efficacy (World Health Organization, 2014). Neuraminidase 
inhibitors, like Oseltamivir and Zanamivir, act on one of the surface proteins, 
neuraminidase, that severs the connection between the new budding virions and the cell 
surface. Inhibition of neuraminidase hinders the liberation of new virions and slows 
through this the rapid growth of virus population (Mckimm-Breschkin, 2013; Wright et 
al., 2013). M2 proton channel blockers, Amantadine and Rimantadine, interfere with 
acidification of the virion that is essential for viral uncoating (Pinto et al., 2006). Anti-
drug resistance has been monitored and high levels have been recorded during the last 
seasons for M2 channel blockers, limiting effectiveness and usage (World Health 
Organization, 2014). Resistance to available anti-influenza medication stresses the need 
for preventive measures. 
2.1.5 Prevention 
An effective way of prevention lies in vaccination. The first influenza vaccines were 
administered in the 1940s (Francis et al., 1945). Influenza vaccines since then and up to 
present times are seasonal. This is to say, that due to antigenic drift composition of 
vaccines need to be reformulated almost every season (World Health Organization, 
2014) and adapted to circulating strains. Selection of vaccine strains is based on 
extensive WHO surveillance but some uncertainty remains (Gerdil, 2003; World Health 





pandemics. In the 2009 pandemic first infections were reported in February in Mexico 
and the first vaccination was available in September 2009 (reviewed in (Wright et al., 
2013)). This is still relatively fast but a gap of half a year without vaccination remains. 
People recommended to receive vaccination include pregnant women, people with an 
age under five or over 65, with chronic medical conditions and health-care workers 
(World Health Organization, 2014).  
2.1.6 Pandemic preparedness 
Pandemic preparedness means taking into account all we can predict about the next 
pandemic and were possible taking action to limit effects and damages. Governments 
like Germany (“Informationen zur neuen Grippe,” n.d., “Nationaler Pandemieplan. Teil 
I,” n.d.) and Great Britain (Barclay, 2017) keep stockpiles of neuraminidase inhibitors 
as one key factor in pandemic preparedness. Concerns remain whether the next 
pandemic strain might be resistant to neuraminidase inhibitors, whether at the time of 
the next pandemic the stockpiled medication is still within its expiration period (Fock et 
al., 2001) and whether the stockpiled amounts might be sufficient. Often delayed 
diagnosis and the above mentioned points stress the need for more preventive actions 
against influenza to achieve greater pandemic preparedness. 
The best prevention, therefore, lies in effective vaccination (Florian Krammer et al., 
2013; Paules et al., 2017; Wright et al., 2013) and is discussed below. 
2.2 Influenza virus 
2.2.1 Types and subtypes 
Influenza virus belongs to the family of orthomyxoviridae viruses. Carrier of influenza 
disease are three known influenza virus types labeled A, B and C. Type A can infect 
humans, but also several animals like birds, swine, dogs and horses. Subtype B is 
known to cause infections in humans, and has been isolated in seals as well (Wright et 
al., 2013). Type C causes only mild symptoms and is of little relevance (Paules et al., 
2017). Influenza A is further divided into subtypes according to their hemagglutinin 
(HA) and neuraminidase (NA). So far 18 hemagglutinin subtypes and 11 neuraminidase 
subtypes have been discovered (Tong et al., 2013). Naming of influenza A subtypes 
follows Hx and Nx, i.e. H1N1 or H3N1. The hemagglutinin subtypes fall into two 
groups, with H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17 and H18 in group 1 





al., 2011). Influenza B comprises two main lineages, Yamagata and Victoria. Up to date 
only influenza A pandemics have been recorded. 
2.2.2 Drift and shift 
Two phenomena of influenza viruses are frequently occurring shifts and drifts. Drift 
describes small changes in influenza genome that occur due to high rates of mutations 
and antibody selective pressure (Florian Krammer et al., 2013), while shift means the 
new combination of surface proteins. During the packaging of new virions in a 
simultaneously with two strains infected host cell, exchanges of surface proteins are 
possible and can lead to new hemagglutinin and neuraminidase combinations. Without 
preexisting immunity, new combinations can lead to pandemics (Medina et al., 2011; 
Paules et al., 2017).  
2.2.3 Structure 
Influenza virions are enveloped and their genetic material is comprised of eight 
negative-sense RNA single-strand molecules. By alternative splicing and alternative 
open reading frames (Shaw et al., 2013) a number of up to 17 proteins can be folded 
(Paules et al., 2017). Important features on the virus surface are two glycoproteins, 
hemagglutinin and neuraminidase. Hemagglutinin mediates binding to host cells by 
recognizing sialic acid residues and enables fusion between viral and endosomal 
membrane (Shaw et al., 2013). Its appearance is divided into a globular head, which is 
the binding site for most neutralizing antibodies, and a stalk or stem region (in this work 
referred to as “stalk”) which is highly conserved. Only recently, neutralizing antibodies 
against hemagglutinin stalk have been discovered (Joyce et al., 2016; Laursen et al., 
2013; Shaw et al., 2013). (Laursen et al., 2013)The second glycoprotein on the virus 
surface, neuraminidase, enables release of new virions from cell surface (Paules et al., 
2017). 
2.2.4 Reproduction cycle 
The reproduction cycle begins with attachment of virus to a host cell, mediated by 
hemagglutinin through binding to a sialic acid residue. Entry occurs through 
endocytosis. Fusion of viral and endosomal membrane is facilitated through a 
conformational change of hemagglutinin and content of the virus can enter the host cell 
through the created pore. Viral ribonucleoproteins are transported into the cell’s 
nucleus, where transcription and replication of virus genome ensues. The newly 





new virions follows. These new virions are actively released from the host cell through 
neuraminidase activity. Released virions can proceed to infect new cells, beginning the 
cycle anew (Shaw et al., 2013). 
2.2.5 Quasispecies 
An important characteristic of influenza virus is its error prone RNA polymerase and 
missing proof reading ability with -5x10^-4 to -8x10^-3 nucleotide substitutions per site 
per year (reviewed in (Wright et al., 2013)). High mutation rates lead to different 
variants of virus simultaneously present in the same host. A mutation can induce greater 
or lesser fitness and a variant with similar fitness as the “main” or originally infecting 
variant can exist in the quasispecies as minor variant. When circumstances change, 
antiviral medication application, presence of antibodies, minor variants with better 
adaptation to these restrictions, for example resistance to the applied antiviral drug, can 
expand to become the major variant within the host. This event is called a bottleneck 
and mutations that allow the virus to escape treatment and proliferate are called escape 
mutants (Domingo et al., 2012). 
When talking about quasispecies and evading mechanisms the language used lets the 
virus appear a thinking and calculating being. This is of course not the case. Virus 
evolution follows simple biological patterns of niches and bottlenecks (Domingo et al., 
2012; Wright et al., 2013). Words used in this work that imply thinking and planning on 
the virus’s part are used for clarification and illustration alone.  
2.3 Influenza Vaccines 
2.3.1 Seasonal influenza vaccine 
Vaccination against influenza started in the 1940s (Francis et al., 1945). There are 
inactivated and live attenuated vaccines available against seasonal influenza viruses 
(Wright et al., 2013). Each year the WHO decides for the Northern hemisphere in 
February and for the Southern hemisphere in September which strains should be 
included (World Health Organization, 2014). The vaccine production finishes around 
six months later so that vaccination can commence before the new influenza season 
starts (Gerdil, 2003). Long time frames between vaccine strain selection and start of 
influenza season carry the risk of mismatches between vaccine strain and circulating 





Vaccines are either trivalent or quadrivalent, with the former containing two influenza 
A subtypes and one lineage B subtype and the latter one containing in addition the other 
lineage B subtype. As an example, for the upcoming season 2017/2018 in the Northern 
hemisphere strains chosen by the WHO to be included in influenza vaccines are an 
A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-
like virus and a B/Brisbane/60/2008-like virus. For the quadrivalent vaccine a 
B/Phuket/3073/2013-like virus is recommended in addition (“WHO vaccine 
recommendations,” n.d.).  
2.3.2 Beyond seasonal influenza vaccine  
Above mentioned obstacles and costs concerning the vaccine production and application 
have let to research efforts going beyond the seasonal vaccine. As explained in the 
previous section vaccine effectiveness is very narrow and strain specific. In the example 
of H1N1 a specific strain (in this year’s vaccine A/Michigan/45/2015 (H1N1)pdm09-
like virus) is chosen for vaccine production. Unfortunately, small changes in the 
genome through drift may result in low protection. A vaccine that would protect against 
all pdm09-like viruses would be an improvement and could well mean less frequent 
administration of vaccine needed. Researchers are aiming even beyond this and search 
for ways of not only protecting against one subtype but its group. That is to say, that a 
vaccine would protect against more than one subtype of group 1 for example (i.e. H1N1 
and H2N2). In addition, the added protection against group 2 strains would be of 
interest and in a next step against pandemic viruses as well (Figure 1). Definition of 
what is a “Universal Influenza Vaccine” has not reached a clear consensus, but 
protection going beyond the seasonal strain has been termed “broadly protective” 
(Nachbagauer et al., 2017; Zhang et al., 2014). In addition, Nachbagauer et al. describe 
a “universal” vaccine as one that confers protection against all influenza A and B 
viruses (Florian Krammer, 2015; Nachbagauer et al., 2017).  
All vaccines giving more protection than can be reached with the seasonal vaccine and 
that need to be administered less frequently signify improvement on this front and might 






Figure 1: Beyond seasonal influenza vaccine. Shown with the example of this year’s H1N1 
strain chosen by the WHO, is the concept of adding to seasonal vaccine to make influenza 
vaccination broader or even universal. 
 
2.3.3 Approaches toward a Universal Influenza Vaccine 
Hemagglutinin is the main target of immune response mediated by antibodies (Shaw et 
al., 2013). It is very important to stress the difference between HA head and HA stalk 
though. The head domain of HA, where most neutralizing antibodies bind, possesses 
high plasticity (Heaton et al., 2013). A very effective mechanism of immune-response 
evasion works through antigenic drift that takes place in the head domain which retains 
function in spite of frequent and various mutations. The stalk region, in contrast, is 
highly conserved (Shaw et al., 2013; Zhang et al., 2014).  
In addition to hemagglutinin, M protein and NP protein have been used in approaches 
toward a Universal Influenza Vaccine (M. Zheng et al., 2014). In contrast to the 
conserved influenza matrix protein and nucleoprotein epitopes, which provide only 
weak protection in human challenge studies (Florian Krammer et al., 2015), the 
conserved stalk portion of HA is a much more potent candidate for a universal vaccine 
(Florian Krammer et al., 2015; Steel et al., 2010; Zhang et al., 2014). In particular, the 
highly conserved long alpha helix (LAH) of the stalk domain spanning amino acid 76- 
130 induces broadly reactive and protective antibody responses (Hauck et al., n.d.; 
Wang et al., 2010). 
One obstacle when intending to use HA stalk as vaccine target is the observation that 
most antibodies produced in an influenza infection are directed against HA head. The 
strains encountered during an individual’s lifetime play an important role in antibody 
production and new antibodies tend to be directed against the same epitopes, a 
phenomenon described as “original antigenic sin” (Vatti et al., 2017). To bypass this 
phenomenon new approaches of HA presentation are under development to elicit 





HA with various, very diverse heads are being used (F. Krammer et al., 2013; Neu et 
al., 2016; Steel et al., 2010). Since the three-dimensional structure plays an important 
role in epitope recognition new possibilities of presenting headless HAs needed to be 
developed as well. One possible way is using virus like particles (VLP) as carriers 
(Blokhina et al., 2013; Peyret et al., 2015). The vaccine that was used in this work was 
designed as part of a Framework 7 European Union program and used iQur’s Tandem 
Core™ technology of virus like particles as carriers for different antigens (“Flutcore 
project outline,” n.d., “Flutcore tandem core,” n.d.; Liu et al., 2016).  
2.4 Next generation sequencing 
Sequencing means determining the order of nucleic acids making up an RNA or DNA 
sequence (Heather et al., 2016). Sanger sequencing, that used to be the predominant 
method of DNA decoding, is being more and more replaced by next generation 
sequencing (Heather et al., 2016). The term is being used for sequencing machines that 
can decode longer sequences in shorter a time. One example and the platform used in 
our work is the IonTorrent sequencer. IonTorrent uses instead of luminescently or 
fluorescently labeled dNTPs the fact that in dNTP incorporation into a newly 
synthesized strand a proton is being released causing a change in pH. In flooding the 
sample with each dNTP individually and registering the change in pH, it is possible to 
determine the order of nucleic acids in a sequence (Bragg et al., 2013; Quail et al., 2012; 
Rothberg et al., 2011).  
At the time this work was performed IonTorrent was able to sequence 400 bp sequences 
with around 5 million reads per run taking around 5 to 7 hours per run (“Ion PGM
TM
 
System Specifications,” n.d.). By now, according to various sources (Greenleaf et al., 
2014; Heather et al., 2016) market leader is Illumina. Illumina uses fluorescently 
labeled nucleotides for paired-end sequencing (Heather et al., 2016). Various new 
approaches have been developed or are in the pipeline (Heather et al., 2016). 
Another aspect of sequencing is the follow up, including data processing and analysis. 
In addition to more precise sequencing techniques new ways of adding to correctness of 
data have been developed. Among them is the method of barcoding (Figure 2). These 
barcodes can be used to label the DNA or RNA of samples and allow this way for 
pooling samples together. Sequencing more samples on the same chip leads to increased 
comparability between samples. More complex and with a key role in error correction, 





The UID consists of a certain number of random nucleotides attached to the beginning 
or the end and in some cases to both sides of a sequence. After amplification and 
sequencing, sequences originating from the same RNA can be traced back and used for 
error correction (Kinde et al., 2011; Vollmers et al., 2013).  
 
Figure 2: Barcoding principle. Through barcoding (14 random nucleotides attached to the 
beginning of sequence, here represented as different symbols) each RNA molecule in the sample 
is labeled uniquely. After amplification different RNAs are present in different copy numbers. 
During amplification and sequencing errors are introduced into sequences. In grouping the 
same UID together (here schematically put as a circle), it is possible to build a consensus 
sequence that resembles the original sequence with high fidelity. 
 
Next generation sequencing produces large amounts of data that need to be analyzed 
effectively to make full use of its potential. Various platforms have been developed and 





2.5 Aim  
With new, broadly protective influenza vaccines on the horizon, questions regarding not 
only efficacy but safety as well arise. Will the presence of antibodies targeting 
conserved regions in a wider population trigger the creation of escape mutations? The 
aim of this work was to gauge the changes in virus population after vaccination 
targeting a specific conserved region. Furthermore, existence of escape mutations was 
to be investigated. So this work, within its boundaries of being performed in mice and 
with one specific vaccine construct, aims at being a proof of concept that a broadly 
protective vaccine against influenza targeting the conserved long alpha helix region of 













 BALB/c mice (Harlan Laboratories, Inc., Horst, The Netherlands)  
3.1.2 Cells 
 Madin-Darby canine kidney cells (American Type Culture Collection) 
3.1.3 Viruses 
 pH1N1(A/Luxembourg/46/2009) 
3.1.4 Solutions, chemicals, reagents 
 Virus growth medium: 500 ml EMEM with Glutamine 
16.5 ml 7.5% BSA 
12.5 ml Hepes 
5 ml Pen-Strep 100x 
500 µl TPCK/ Trypsin 
 TPCK (Sigma-Aldrich, Diegem, Belgium) 
 Agencourt® AMPure® XP beads (Beckman Coulter, Suarlée, Belgium) 
 MF59/Addavax® (Invivogen, Toulouse, France) 
 DTT (ThermoFisher Scientific) 
 Q5® High GC Enhancer (NewEngland BioLabs, Ipswich, Massachusetts) 
 MDCK medium:   500 ml EMEM with Glutamine  
50 ml FBS 
5 ml Pen-Strep 
12.5 ml HEPES 
 
 





 Superscript® IV (ThermoFisher Scientific) 
 Phusion® (NewEngland BioLabs®, Ipswich, Massachusetts) 
 Q5® (NewEngland BioLabs®, Ipswich, Massachusetts) 
 RNAse OUT™ (ThermoFisher Scientific) 
3.1.6 Commercial kits 
 QIAamp® Viral RNA Mini kit (Qiagen, Hilden, Germany) 
 Ion PGM™ Template OT2 400 kit (ThermoFisher Scientific) 
 Ion PGM™ Sequencing 400 kit (ThermoFisher Scientific) 
 Ion 316™ and 318™ chip kits v2 (ThermoFisher Scientific) 
3.1.7 Buffers 
 Superscript® IV First Strand Buffer (ThermoFisher Scientific) 
 Phusion® Buffer (NewEngland BioLabs®, Ipswich, Massachusetts) 
 Q5® Reaction Buffer Pack (NewEngland BioLabs®, Ipswich, Massachusetts) 
3.1.8 Primers 
 Forward primer: 5’ CACAGTTCACAGCAGTAGGTAAAGA 3’ 
 Reverse primer: 5’ ATTGCCCCCAGGGAGACTAC 3’ 
 MID07: TTCGTGATTC 
 MID11: TCCTCGAATC 
 MID19: TTAGTCGGAC 
 MID30: CGAGGTTATC 
 A Adapter: 5’ CCATCTCATCCCTGCGTGTCT 3’ 
 P1 Adapter: 5’ CCTCTCTATGGGCAGTCGGT 3’ 
3.1.9 Instruments 
 Agilent Bioanalyzer 2100 (Agilent Genomics, Santa Clara, California) 
 IonTorrent PGM™ (ThermoFisher Scientific) 
 Ion OneTouch™ 2 System (ThermoFisher Scientific) 
 Qubit® 2.0 Fluorometer (ThermoFisher Scientific) 
 IonTorrent ES™ (ThermoFisher Scientific) 
 NanoDrop™ (Thermos Scientific™) 
 TissueLyser II (Qiagen, Hilden, Germany) 




 Thermocycler UNO96 (VWR®) 
 PURELAB® flex 3 and 4 Water Purification Systems (ELGA LabWater) 
3.1.10 Software 
 Pymol (The PyMOL Molecular Graphics System, Version 1.7, Schrödinger, 
LLC.) 
 ID-50 5.0 program 
(http://www.ncbi.nlm.nih.gov/CBBresearch/Spouge/html_ncbi/html/index/softw
are.html#1) 
 BioEdit V7.2.5 (Hall, T.A. 1999. BioEdit: a user-friendly biological sequence 
alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. 
Symp. Ser. 41:95-98) 
 GraphPad Prism 5 (San Diego, CA, USA) 
 Biopython V 1.66 (http://biopython.org/)  
 Python V 3.5 (https://www.python.org/)  
 MAFFT  V 7.273 (http://mafft.cbrc.jp/alignment/server/)  
 FASTX-Toolkit V 0.0.13 (http://hannonlab.cshl.edu/fastx_toolkit/)  
 Geneious V R8.1 (http://www.geneious.com, Kearse et al., 2012) 
 RStudio V 1.0.153 (RStudio Team (2015). RStudio: Integrated Development for 
R. RStudio, Inc., Boston, MA URL http://www.rstudio.com/.) 
 Mendeley V 1.17.10  
(https://www.mendeley.com/reference-management/reference-manager) 
3.2 Methods 
3.2.1 Mouse work 
Animals were housed in an ASL3 animal facility. Feeding and cleaning of cages was 
performed following a regular scheme. Weighing before challenge was done once a 
week and after challenge every day to monitor weight loss and to determine end point of 
the experiment for individual mice and their sacrifice time.  
All mouse experiments were performed in accordance with protocols approved by the 
Animal Welfare Structure of Luxembourg Institute of Health and by the Minister of 
Agriculture, Viticulture and the Consumer Protection of the Grand Duchy of 
Luxembourg (Ref. LNSI-2014-02) (Hauck et al., n.d.). 
 




3.2.2 Virus culture 
MDCK cells were cultured to be used in lung titer determination. To this end trypsin 
and medium were warmed in a water bath and confluency of cells was checked under a 
microscope. The old medium was removed with a pipette and 1 ml trypsin was added to 
remove cells from surface of the flask. The flask was then put in a 37°C incubator and 
left there for 5 to 10 minutes depending on the cells still attached to the surface, which 
was checked again by microscope. 9 ml of fresh medium were added to the flask and 
cells now resuspended in medium and trypsin were transferred to a Falcon tube and 
centrifuged for 5 minutes at 1200 rpm and room temperature. The supernatant was 
removed and cells resuspended in 1 ml of fresh medium. For a dilution of 1:6 another 5 
ml of medium were added and then 1ml of suspended cells transferred to a new flask 
with 20 ml medium. 
3.2.3 Virus challenge 
Eight week old BALB/c mice received three times immunization with LAH-HBc 
chimeric proteins containing long alpha helix of pH1N1 (A/Luxembourg/46/2009, 
pH1N1) and MF59 (Invivogen, Toulouse, France) in two weeks intervals. Mock group 
mice received adjuvant only. Two weeks after the final immunization, mice were 
challenged with 5 x 50% Mouse Lethal Dose of pH1N1 intranasally, after anesthesia 
with isoflurane (Lu et al., 2017). Mice were sacrificed 5 days post infection (n=3 for 
mock, n=6 for immunized) or 7 days post infection (n=2 for mock, n=3 for immunized) 
for organ removal (Hauck et al., n.d.) (Figure 3). 
 
 
Figure 3: Scheme of mouse immunization and virus challenge. Two groups (“immunized” and 
“mock”) were immunized days 0, 14 and 28. Two weeks later animals were infected and 
sacrificed 5/ 7 days post infection (Hauck et al., n.d.). 
 




3.2.4 Organ extraction 
Mice were sacrificed by cervical dislocation and directly prepared for organ removal by 
spraying them with ethanol. A pair of scissors was used to separate the skin from the 
peritoneal wall. At the sternum the ribcage was cut open until the neck. Cutting off the 
ribcage to the sides of the incision was followed by carefully lifting lungs and heart 
together with forceps out of the chest cavity. Lungs were disconnected from heart and 
remaining tissue. The lungs were put into a 2 ml safe-lock tube with a shredding bead 
and 0.9 ml VGM. Lungs were not stored but directly processed for RNA extraction and 
virus titer determination (Figure 4). 
 
 
Figure 4: Assays performed on lung samples from immunized and mock immunized mice. After 
extraction lungs were used for lung viral titers and viral RNA extraction. Viral RNA was 
sequenced on an IonTorrent PGM platform (Hauck et al., n.d.). 
 
3.2.5 Lung titer 
Explanted lungs (n=14) were homogenized in 900 µl virus growth medium for 12 
minutes at 25 Hz and centrifuged for 10 minutes at 11,000 rpm (Theisen et al., 2012). 
TCID50 in the supernatant was determined on Madin Darby canine kidney cells. 
Wildtype pH1N1/09 virus was cultured on MDCK cells in serum free growth medium 
that contained 2mg/ml L-1-tosylamido-2-phenylethylchloromethylketone trypsin. 50% 
TCID determinations of virus were performed on MDCK cells by incubating them in 




quadruplicates for 20 hours with 8-fold serial dilutions of virus-containing supernatant 
at 37°C and 5% CO2, and were calculated by the ID-50 5.0 program (Hauck et al., n.d.). 
3.2.6 RNA extraction 
RNA was extracted from wildtype virus and from the supernatant of the homogenized 
lungs using the QIAamp® Viral RNA Mini kit. First, lung tissue was homogenized in a 
TissueLyser at 25 Hz for 12 minutes. Afterwards tubes were centrifuged at 11,000 rpm 
for 10 minutes and supernatant was pipetted off for RNA extraction. The following 
steps were performed according to the manufacturer’s protocol. 560 µl AVL Buffer 
(included in kit) containing carrier RNA were pipetted into a 1.5 ml tube and heated at 
80°C for 5 minutes to dissolve any precipitates. 140 µl of sample were added to the 
buffer and pulse-vortexed for 15 seconds. The mixture was left to incubate at room 
temperature for 10 minutes and afterwards briefly centrifuged to remove any droplets 
from lid. 560 µl of 100% ethanol were added, mixed by pulse-vortexing for 15 seconds 
and again briefly centrifuged. Half of this mixture (630 µl) was transferred to a 
QIAamp® mini column (included in kit) that sat on a 2 ml collection tube and 
centrifuged at 8,000 rpm for 1 minute. The 630 µl still left of the sample mixture were 
likewise transferred to the column and centrifuged. The filtrate was discarded and the 
column placed on a new collection tube. Afterwards, 500 µl of AW1 Buffer (also 
included in kit) were added and the column with collection tube centrifuged at 8,000 
rpm for 1 minute. The filtrate was again discarded and the column placed on a new 
collection tube. This time 500 µl of buffer AW2 (included in kit) were added and the 
centrifuge set to 14,000 rpm for 3 minutes. The filtrate was discarded, the column 
placed on a 1.5 ml tube and 60 µl AVE buffer as final eluent added. Final centrifugation 
was done at 8,000 rpm for 1 minute (“QIAamp® Viral RNA Mini Handbook,” n.d.). 
The quality of extracted RNA was analyzed employing an Agilent Bioanalyzer 2100 
RNA kit. 
RNA extraction and handling of virus were performed under Biosafety level 3 
conditions.  
3.2.7 Library preparation 
For sequencing on the IonTorrent platform samples needed to be prepared in a specific 
way. The libraries for sequencing were prepared using an adapted protocol from 
Bürckert et al. (paper under preparation (Bürckert, n.d.)) and (Kinde et al., 2011; Loman 
et al., 2012; Vollmers et al., 2013).  




Reverse transcription was performed on 100- 200 ng virus RNA: 
1-10 µl of template 
1 µl dNTPs 
1 µl forward primer  
Adding water to reach 13 µl of mixture in total 
Cycler: 5’ 65°C, incubation on ice for 1 min 
Adding:  
4 µl FirstStrand Buffer 
1 µl DTT 
1 µl RNase OUT™ 
1 µl Superscript® IV 
Cycler: 10’ 55°C, 10° 80°C 
The primer for reverse transcription was linked to a unique identifier (UID) consisting 
of 14 random nucleotides which enables the recognition of every original mRNA strand 
after amplification (Figure 5). The primer was connected to four different mouse 
identifiers (MID) to allow pooling samples from different mice on a single sequencing 
chip. Furthermore, the primer contained a short sequence of IonTorrent A-Adaptor. 
After reverse transcription the second strand synthesis was performed on half the 
outcome of reverse transcription: 
5 µl Phusion® Buffer 
1 µl dNTPs 
1 µl reverse primer 
7 µl water 
1 µl Phusion® 
10 µl template 
Cycler: 2’ 98°C, 2’ 50°C, 10’ 72°C 
The reverse primer was connected to a short sequence of IonTorrent P1-Adaptor. After 
second strand synthesis and before amplification, the samples were purified twice with 
Agencourt® AMPure® XP beads at a ratio of 1:1.  




For the final amplification step of the library Q5® enzyme in combination with a primer 
mix of A-Adaptor and P1-Adaptor was used:  
5 µl Q5® Buffer 
5 µl GC enhancer 
1 µl dNTPs 
0.5 µl primer mix 
3 µl water 
0.5 µl Q5® 
10 µl of template 
Cycler: 5’ 98°, 20x (10’’ 98°, 20’’ 65°, 30’’ 72°), 2’ 72°  
The finished library was purified once with Agencourt® AMPure® XPbeads before 
being analyzed for both quality and quantity on Agilent Genomic’s Bioanalyzer 2100 
before deep sequencing (Hauck et al., n.d.). 
 
 
Figure 5: UID method in library preparation. Shown is the UID method as applied in library 
preparation (Hauck et al., n.d.).  
 
 




3.2.8 Sequencing preparation 
Libraries of two immunized and one mock mouse were pooled to be sequenced on the 
same chip. Wildtype virus libraries were done in triplicates and pooled together (Hauck 
et al., n.d.). Pooling was done to minimize discrepancy between samples because of 
differences in loading or other sequencing steps and in a way that the same 
concentration of RNA from each sample would be used. Template preparation was done 
using the Ion PGM™ Template OT2 400 kit, according to manufacturer’s instructions, 
using the Ion OneTouch™ 2 System, Qubit® 2.0 Fluorometer and IonTorrent ES™ for 
enrichment. 
3.2.9 High-throughput next generation sequencing 
For sequencing the Ion PGM™ Sequencing 400 kit and Ion 316/318 chip kits v2 were 
used.  
For all steps related to IonTorrent or preparation for IonTorrent sequencing, protocols 
were followed as indicated by LifeTech (Paisley, UK). 
3.2.10 Data processing 
An in house pipeline was built to process and analyze IonTorrent data that we obtained 
(Figure 6).  
A few preparatory steps were needed before running the main part of the pipeline 
(“variants.py”). In order to normalize for differences between sequencing runs, similar 
to the principle of quantile normalization (Bullard et al., 2010; Rapaport et al., 2013), 
we compared the percentage of reads with a minimum coverage of three (three was 
chosen because consensus building requires at least three copies) for every chip. A 
minimum UID copy number for a sequence to be included into data analysis per chip 
was calculated, so that the same percentage of reads (33%) from every chip would be 
used. The threshold of 33% was determined by checking for every chip the percentage 
of reads with a copy number greater or equal to 3 and then selecting the lowest 
percentage of all chips. This task was performed by Python script 
“distribution_threshold.py” (see Annex (7.3.1)).  
To overcome the heterogeneity in copy numbers among different UIDs, we calculated 
how many sequences needed the same nucleotide at the given position, for the 
nucleotide to be the consensus character for this position. For example, to build a 
reliable consensus sequence from only 3 copies for a given UID, a minimum of 2 need 




to be the same to define a reliable nucleotide read. The thresholds were calculated 
individually for every coverage using the cumulative binomial distribution, with 
q=0.015625, and α=1-q. Cumulative binomial distribution was used to create a list that 
assigns the copy number needed to always reach the same probability to every possible 
UID copy number. This list was used in the main script (“variants.py”) for consensus 
building.  
In the main script (“variants.py”) (see 7.3.2) trimmed BAM files exported from 
IonTorrent platform were imported. The pipeline was used to filter out poor quality 
reads and to correct for homopolymer errors. In a first quality filtering step, reads with 
20% less than the expected length were filtered out and only reads which had more than 
95% of nucleotide positions with a minimum quality score of 20 were kept for further 
analysis. After splitting the reads coming from the different samples according to their 
MIDs, they were grouped into reads originally coming from the same mRNA molecule 
by using the UIDs. Errors in poly-A-sequences were corrected to forestall the most 
commonly reported errors in IonTorrent sequencing (Bragg et al., 2013). Since the three 
poly-A-sites within our sequence were composed of repeats of 6 nucleotides, we 
uniformed all the sequences by correcting those with 5 or more than 6 repeating 
nucleotides at these positions to ones with 6 nucleotides. Sequences were cut to include 
only the epitope that the vaccine construct targets. Within each selected UID family we 
aligned reads using MAFFT and built a consensus sequence using Biopython 
(gap_consensus) with the thresholds from our list obtained with cumulative binomial 
distribution (Hauck et al., n.d.). 





Figure 6: Data processing steps. The different steps our data processing pipeline was comprised 
of are listed (Hauck et al., n.d.). 
 
The main script (“variants.py”) was called individually for every pool. The variables to 
be set included the input file (BAM), a prefix to recognize data from the specific input 
file (this prefix was added to all files generated in this run of the script), the forward and 
backward “primer” used to recognize the region of interest, the UID threshold (all reads 
with a coverage below threshold were discarded) calculated in 
“distribution_thresholds.py”. Furthermore it was possible to decide whether quality 
correction or poly-A-site correction should be performed (these steps were used in all 
pools) and the list of how many copies of a certain UID needed to be the same to build a 
consensus sequence were given as tsv file. Some variables were set to a default value, 
like the minimum and maximum required sequence lengths (270 and 500, respectively), 
the minimum quality a base should have (20) and the percentage of bases within a 
sequence which should have the minimum quality (95%) (as described above). 
For pipeline see Annex (7.3 Pipeline for data processing). 
3.2.11 Data analysis 
Geneious and BioEdit were used to convert the nucleotide sequences into amino acid 
sequences and to study mutations. The Shannon diversity index was calculated (Luo et 




al., 2012) to determine diversity of quasispecies population. All sequences, including 
the ones having frameshifts or stop codons (1-2% of final sequences) were included in 
the diversity calculations. The heatmap (Figure 12) showing each diversified amino acid 
position on LAH epitope was generated using R program. Values for each mutation 
have first been normalized by determining the percentage of total consensus sequences 
they make up in the individual samples before a clustering analysis (Hauck et al., n.d.). 
3.2.12 Statistical analysis 
In GraphPad Prism 5 multiple t-tests, unpaired t-test, and one-way ANOVA followed 
by Tukey’s as post-hoc test were used to determine statistical significance. P value less 









4.1 Protection against influenza A virus challenge 
Female BALB/c mice were challenged with H1N1 and weight was controlled every 
day. In previous experiments in our lab, performed by I-Na Lu and Sophie Farinelle, 
extensive protection could be shown against both strain specific challenge and various 
other strains, including even protection against challenges with strains from other IAV 
group (Figure 7)(Hauck et al., n.d.).  
 
 
Figure 7: Protection against different IAV strains. Protection conferred against lethal challenge 
of 5x MLD50 of either pH1N1 (A/Luxembourg/46/2009) or H3N2 (A/Aichi/68) virus. Mock mice 
were vaccinated with adjuvant only. Mice vaccinated with LAH-HBc chimeric proteins (A and 
B) showed 100% survival after pH1N1 challenge and 75% survival after H3N2 challenge (C 





4.2 Reduced lung virus titers in immunized mice 
After immunization animals were challenged intranasally with 5 x MLD50 of influenza 
A virus and the viral load was measured in the lung 5 and 7 days post infection. A 
significant difference in virus lung titers emerged on 7 days post infection between 
immunized and mock animals (Figure 8) (Hauck et al., n.d.).  
 
 
Figure 8: Lung titer. Lung virus titers of mice 5 days post infection and 7 days post infection. *P 
< 0.05. Error bars represent standard error of the mean (SEM) (Hauck et al., n.d.). 
 
 
4.3 Presence of influenza RNA and sample input determination for 
libraries 
Lungs were explanted after sacrifice and virus RNA was extracted. The extracted RNA 
was tested by PCR analysis by Aurélie Sausy to certify the presence of influenza virus 





Extracted RNA was quantified on NanoDrop™ and the best amount of starting material 
had to be determined. In the end about 100 ng of wildtype virus RNA and between 100 
ng and 1750 ng of mouse sample RNA were used to prepare at least three libraries for 
each sample. The library used for sequencing was chosen by library quality determined 







Figure 9: Quality control on Bioanalyzer. On the example of lung 32 are shown the Bioanalyzer 







4.4 Sequencing quality 
Chip loading influences the number of raw reads that can be achieved in sequencing 
(Figure 10).  
 
 
Figure 10: Chip loading. Two examples of chip loading and raw read output (at the top Pool 22 
and at the bottom Pool 28). 
 
For number of raw reads, reads for consensus building after clean-up, consensus 
sequences and number of unique consensus sequences see Table 1: Sample properties.  
4.5 Decreased diversity of long alpha helix epitopes  
The virus on a population level was further characterized on 5 dpi and 7 dpi using next 
generation sequencing. The overall diversity of viral quasispecies in the LAH domain in 
the different groups was calculated using the Shannon Diversity Index. The wildtype 
virus expanded in vitro on MDCK cells showed the highest variability within the tested 
region. On 5 dpi, viruses from the lung of immunized mice showed significantly less 





demonstrate that in the animals the virus loses diversity and that this effect is more 
dramatic in immunized mice than in the control group. Inversely, when comparing the 
diversity of nucleotides with amino acids, the ratio was significantly increased on 5 dpi 
in the immunized mice compared to the wildtype virus and mock animals. Thus, in the 
immunized animals the virus has more synonymous mutations compared to the one 
from the wildtype virus and the mock group (Hauck et al., n.d.) (Figure 11). 
 
 
Figure 11: Levels of diversity in comparison between different groups. Lung viruses of 
vaccinated mice showed a reduction in LAH sequence diversity. (A) Shannon diversity index of 
LAH amino acids. †: corresponding to the samples with the same labeling in Fig. 12B. (B) 
Nucleotide to amino acid entropy ratios of the Shannon diversity calculated for each sample. *P 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.6 Absence of escape mutants following vaccination 
To understand the observed differences in quasispecies diversity, the missense 
mutations in the different groups were examined. In order to select for relevant 
mutations only, we focused on those that appeared in at least 3 of the 18 samples. With 
this approach 212 possible amino acid exchanges within the analyzed epitope, which 
covered all 55 positions were found. A heatmap was generated to compare the 
occurrence of these missense mutations between the groups (Figure 12). Hierarchical 
clustering based on these occurrence levels resulted in three major clusters, one 
composed only of wildtype virus samples, a second one composed only of samples from 
immunized mice and a third one containing  all mock samples and two of the 7dpi 
samples from the immunized group. This observation could be further confirmed by 
principle component analysis (PCA) to the frequencies of mutants among different 
groups. The marked two 7dpi samples showed a similar level of diversity as in the mock 
mice. An overall gradual decline in mutated virus sequences can be observed when 
comparing the wildtype virus, mock and immunized samples, confirming again the 







Figure 12: Constrained viral quasispecies evolution under immune pressure. (A) Heatmap of 
missense mutations detected in at least three out of the eighteen samples analyzed. Values from 
each row (i.e. mutation) have been normalized to have a mean of 0 and SD of 1 and relative 
expression levels of the same mutation within the individual mice are represented by the color 
code indicated in the legend at the top right. (B) Hierarchical clustering analysis performed 
using complete linkage and Euclidean distance measurement. †: corresponding to the samples 
with the same labeling in Fig. 11A. (C) Mean sequence composition of samples per group. The 
sizes of the bubbles are proportional to the mean percentage sample consensus sequences of 






4.7 Identification of diversified positions on long alpha helix epitope 
In order to extract the most significantly mutated positions of the analyzed epitope, the 
Shannon diversity index was calculated for every amino acid position across the LAH 
epitope (Fehler! Ungültiger Eigenverweis auf Textmarke.). This way, 11 different 
positions were identified to reach statistical significance when comparing the groups 
using a two-tailed student’s t-test. At each of these positions, except for position 123, 
the immunized group showed a lower or similar aa diversity as compared to the mock 
mice. Amino acid positions 85 and 96 were particularly variable in the cultured virus, 
but this was lost in the in vivo virus populations. Variability in these two positions was 
the major contributor to the differences in diversity observed between the groups as 
confirmed by PCA analysis. Positions 121 and 124 seem to be generally more diverse 
but with little difference between groups. The PCA analysis showed very different 
diversities among in vitro and in vivo samples. However, the differences between Mock 
and Immunized mice were not clearly distinguishable by using the Shannon diversity 
index alone, indicating the need of more detailed analysis on the amino acid 









































































































































4.8 Analysis of amino acid substitutions  
To identify the mutations that were selected by the vaccine-induced immune pressure, 
all the identified 212 amino acid exchanges were compared between the Immunized and 
the Mock groups. Five mutations were found with significantly different frequencies 
between the groups: D85N, A96V, D112N, K121E, and N129S (Figure 14). Each of 
these amino acids showed a significantly reduced frequency in the immunized animals. 
No mutant variant emerged that replaced the dominant viral sequence in any of the 
samples. There were, however, significant differences in the occurrence of the dominant 
viral sequence between groups (Figure 15), suggesting a constrained viral quasispecies 
evolution in the Immunized group (Hauck et al., n.d.). 
 
Figure 14: Crystal structure of hemagglutinin. The crystal structure of H1 subtype (PDB: 3AL4) 
was used to map the positions of significant missense mutations on the HA monomer by PyMOL 
software. The colored region represents the LAH epitope. Slate blue denotes the heptad repeat 
region, pale green represents conformational change region with the H contributing to 
histidine-rich patch labeled in orange, and the remaining of the epitope is colored in pink 
(Sriwilaijaroen et al., 2012). The mutations denoted in black are mutations for which a 
statistically significant difference in occurrence was observed when comparing immunized with 














































































































































In the present work, NGS was applied to directly follow the in vivo IAV quasispecies 
evolution in response to humoral immunity to long alpha helix, a conserved 
hemagglutinin stalk epitope. In agreement with previous studies conducted by Wang et 
al. and Zheng et al., our LAH targeting vaccine elicited significant seroconversion and 
protection against homologous and heterologous IAV strains in mice (Wang et al., 
2010; D. Zheng et al., 2016). The virus quasispecies found after vaccination showed a 
significant reduction in amino acid variability in the LAH domain and no escape mutant 
emerged. These findings provide further evidence for LAH as a potential vaccine 
candidate and as proof of concept for a Universal Influenza Vaccine that can control 
influenza A virus without enhanced propensity for escape mutants within the 
investigated region (Hauck et al., n.d.).  
5.1 Summary 
Influenza is a serious threat to global health and economy. It is unlikely humankind 
could eliminate influenza but we can certainly strive to lower the burden and improve 
influenza preparedness. Going new ways in vaccination techniques, there is a need to 
know what our work might entail. Part of this is being aware and taking responsibility 
for how we influence the evolution of influenza. When putting pressure on a virus, in 
form of antiviral drugs or antibodies targeting the virus, evading mechanisms arise 
(Florian Krammer et al., 2013). Antiviral drugs like M2 channel blockers have let to a 
growing population of resistant viruses (World Health Organization, 2014). Seasonal 
influenza vaccines targeting the head region of HA lead to similar changes in population 
which the virus population can circumvent through antigenic drift and shift. It would be 
naïve to not consider similar evolution after vaccination against conserved regions. The 
question following out of this observation is whether new vaccination approaches 
targeting conserved regions might serve as the pressure that will give the incentive for 
the virus to escape. The hemagglutinin might be more conserved because of very 





need to change so far because conserved regions were not targeted frequently by the 
immune system. Already Chai et al. have shown that evading mechanisms are possible 
though (Chai et al., 2016). The evading mechanisms discovered so far were observed in 
in vitro studies and meant less fitness for the virus. It remains to be shown what the 
evolution in vivo and in the long run might be. The mouse model is a sound depiction 
(Frise et al., 2016) but an interesting further approach would be an in vivo study with a 
ferret model which allows for inter-individual infection cycles similar to humans (Frise 
et al., 2016). In a study like that it would be interesting and possible to find out which 
mutants might keep fitness to infect effectively. Furthermore, some discoveries as to the 
virus’s reaction might only be made after vaccination against conserved regions 
becomes widely available and used.    
5.2 Quasispecies and virus growth dynamics 
The population dynamics of multiple IAV strains have been well documented in both 
humans and mice (Grenfell, 2004). Chai et al. used antibodies against conserved regions 
of HA to select for escape mutants and tested them in vivo (Chai et al., 2016). In 
contrast to our findings, Chai et al. could identify two possible escape mechanisms, 
although with reduced fitness for the escape mutations. Here, we used a murine 
infection model to investigate the changes of lung virus quasispecies under the pressure 
of antibodies targeting LAH. Unvaccinated animals failed to control IAV replication in 
the lungs and died at 7 dpi due to serious pulmonary damage. In response to the 
vaccination, viral kinetics followed a course similar to the one described in previous 
studies (Grenfell, 2004). Viral replication in the lungs became detectable at 3 dpi, 
peaked at 5 dpi, and began to decrease at 7 dpi. For this reason, we examined lung virus 
quasispecies at both peak (5 dpi) and reduced (7 dpi) viral replication (Hauck et al., 
n.d.). 
We observed an increased proliferation of influenza virus at 5 dpi and a rapid viral 
clearance at 7 dpi in lungs of the immunized mice, while viremia persisted in the lungs 
of the mock animals at both time points (Figure 8). These results are in accordance with 
previous observations that a short but rapid proliferation of IAV in mice with a stronger 
immunity leads to enhanced activation of the acquired immune system, which 
ultimately results in fast viral clearance (Hernandez-Vargas et al., 2014; Pawelek et al., 
2012). A well-known bottleneck effect (Bull et al., 2011; Domingo et al., 2012) that is 





observed in viral evolution studies under host immune selection. In this study, a similar 
bottleneck effect was also observed, which reduced amino acid diversity of virus 
quasispecies in the LAH domain. However, an unexpected preferential proliferation of 
viruses with non-mutated LAH in immunized mice was shown in the analysis. These 
findings demonstrate that single or few mutations on LAH do not allow influenza virus 
to survive or to become resistant, and the vaccine did not favor any expansion of escape 
mutants (Hauck et al., n.d.). 
Apart from antibodies other reasons play into the way that the quasispecies changes. 
Certain characteristics of the individual mouse might influence viral clearance and 
severity of infection. Those factors were not controlled for in this study. In addition, in 
the present study design it was not possible to control the outcome since mice that 
survive would have cleared lungs with no RNA for sequencing. 
RNA viruses have a high mutation rate which in influenza A in particular has been 
calculated to be -5x10^-4 to -8x10^-3 nucleotide substitutions per site per year 
(reviewed in (Wright et al., 2013)). Thus, we would expect to find escape mutations 
within one cycle of infection in mice, if escape mutations should arise. Of course, a 
longer observation time frame might lead to additional findings and might be needed to 
definitely rule out any appearance of fit escape mutants.  
The Shannon diversity index has been used to follow quasispecies evolution (Gregori et 
al., 2016). Other possibilities of describing the evolution of quasispecies include various 
other indices (e.g. minimum mutation frequency or population nucleotide diversity) 
(Gregori et al., 2016). The methods of  quasispecies’ description remain limited as long 
as sequencing the whole genome of all virions present at the same time is not feasible 
(Gregori et al., 2016). This remains a field of further studies and might render new 
insights into quasispecies in the future. 
5.3 Next generation sequencing and data processing 
Next generation sequencing is a fast evolving field, applied for various and increasing 
numbers of studies. Likewise, NGS is on its way of becoming the gold standard for viral 
quasispecies observations (Barzon et al., 2011). Here, development of techniques and 
their respective evaluation is still in progress. This includes error rates and processing 
pipelines. IonTorrent, as one of different next generation sequencing approaches, holds 





to other NGS platforms IonTorrent is prone to indels but has a low propensity for 
substitution errors (Goodwin et al., 2016). Indel errors could be reliably removed by 
comparison to the IAV reference sequence. When deciding how to best build consensus 
sequences IonTorrent data have the advantage and disadvantage of specific errors in 
specific situations (Bragg et al., 2013). When errors are not random but occurring in the 
same positions consensus building has limitations. On the other hand knowing what 
errors to expect three potentially challenging regions with homopolymer A sequence 
could be identified and corrected specifically to facilitate an efficient consensus 
building. Since low levels of mutations were of primary interest, substitution errors 
were further reduced  by applying a barcoding technique that allows tracing back of 
individual RNA strands (Kinde et al., 2011; Loman et al., 2012). This technique also 
allowed pooling of samples from different groups on a single sequencing chip to 
minimize differences caused by chip loading. Inter-chip normalization enabled the 
removal of any further factor that could influence reproducibility (Rapaport et al., 2013) 
(Hauck et al., n.d.).  
An in-house pipeline was established so that meeting the exact requirements of this 
work would be possible. As a small drawback the pipeline was not validated on other 
data sets for cross checks. With multiple tests on smaller parts of our data between 
pipeline steps and careful building of the pipeline, we added to a reliable processing 
procedure.  
As another drawback of using IonTorrent in the set-up of this work, sequencing length 
was limited to a few hundred base pairs which made monitoring of all mutations 
throughout the whole genome impossible. This study therefor focused on the target 
epitope. In this region of greatest interest due to the antibodies targeting the region, no 
escape mutations could be shown. It is however possible that escape mutations could 
occur in other regions than the targeted one, so for the future it would be desirable to 
sequence the whole influenza genome in order to control all possible mutation sites. 
Here, further studies are needed to confirm and extend our promising findings (Hauck et 
al., n.d.). 
5.4 Mutations and variability 
According to Brooke et al. a large number of virions in an infected host are not 
assembled completely (less than the normal 8 RNA strands) (Brooke et al., 2013). In 





would make a proper assembly of HA protein impossible. These variants were included 
in quasispecies diversity calculation because they could be seen as “attempts of escape” 
but not in showing mutants since virions without a functioning HA would not be able to 
infect a new cell and thus pose no threat of replicating and making up large portions of 
the quasispecies as escape mutants (Hauck et al., n.d.). 
With the set-up of this work, previous discoveries could be confirmed. For example, a 
mutation S124N was identified that was present in all samples analyzed with relatively 
high prevalence (0.37%-0.41% in “wildtype virus”; 0.16%-0.35% in “Mock”; and 
0.04%-0.36% in “Immunized”). This mutation was also sporadically found in humans 
during the 2009-2010 season and became dominant during the 2011/2012 influenza 
season (Lee et al., 2015), which further supports the robustness of our approach (Hauck 
et al., n.d.). 
When comparing the Immunized and the Mock group, five mutations showed a 
significantly different prevalence. Each of these mutations was less frequent in the 
immunized than in the mock animals. These mutations were scattered across three 
different regions (Sriwilaijaroen et al., 2012) of the LAH domain: D85N and A96V 
were found in the heptad repeat region, D112N in the conformational change region, 
and K121E and N129S in a non-functional region. The latter two mutations were also 
situated on a previously identified CD4 T-cell epitope of BALB/c mice (Lu et al., 
2017). Whether or not the immunization had an impact on the reduction of these 
mutations will require further experiments for illustration. Altogether, neither was an 
increase in diversity as a result of the virus escaping the immune response observed, nor 
was a replacement of the dominant viral sequence by a mutant strain seen. This suggests 
that viruses failed to generate functional mutated LAH proteins. The absence of major 
non-synonymous substitutions within this region indicates that the amino acid 
composition is highly restricted. This is in line with the extensive conformational 
changes that the LAH undergoes during viral growth (Hauck et al., n.d.; Sriwilaijaroen 
et al., 2012). 
5.5 Medical relevance and outlook 
Universal Influenza Vaccines are still at the beginning. Careful planning on what is 
needed (broadly protective versus universal), further investigation of conserved epitopes 





One control that might be of interest but not conceivable in the set-up of this study is a 
control group vaccinated with seasonal influenza vaccine. Seasonal vaccines have been 
shown to neither induce stalk specific antibodies (Florian Krammer et al., 2015) nor 
mutation on stalk domain in human (Lee et al., 2015). Therefore, the finding of escape 
mutations in the stalk region of hemagglutinin following seasonal influenza vaccination 
was not to be expected. In addition, at the chosen time point for viral quasispecies 
investigation, antibodies induced by seasonal vaccine have cleared too much virus from 
the lungs to effectively extract and analyze virus RNA (Hauck et al., n.d.). In this 
specific set-up a comparison with a control group receiving seasonal vaccine would not 
have given interpretable results. Nevertheless, universal vaccines need to be judged on 
their additional benefit compared with seasonal vaccines and further investigation into 
the appearance of escape mutants might have to be included in new study set-ups. Now 
that it is becoming conceivable to sequence the whole genome it would be very 
promising to repeat experiments looking not only at the region of greatest interest but 
also at escape mutations that may arise by heightening the efficacy of other viral 
proteins. Another interesting aspect would be the study of simultaneous mutations that 
together, as permissive mutations, might confer protection from vaccine induced 
antibodies. Here, obstacles have to be overcome because simultaneousness of mutations 
would have to be shown on the same virion or population of viruses.  
In summary, reaching beyond the vaccination we have at our disposal is a step of 
financial and health care interest. New questions and concerns arise and call for further 
investigation. This work was done as one step in this direction to find out whether 
vaccination against a conserved epitope region will induce escape mutations. It might 
only be one small part of what needs to be done before we can rule out any harmful 
outcomes of this new vaccination program. But in its context this work is a promising 
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#                                                                              # 
#                                  imports                                     # 
#                                   input                                      # 
#                                 functions                                    # 






#input distribution files 
distribution_folder = sys.argv[1] 
min_read_coverage = 3 
 
given_reads = {} 
#given_reads["18"] = 3682546 
given_reads["21"] = 1731069 
given_reads["22"] = 5835938 
given_reads["24"] = 4293287 
given_reads["26"] = 4458459 
given_reads["28"] = 5249236 
given_reads["30"] = 5316885 
 
#This function reads in a file and saves everything into the two given 
#dictionaries. 
#One contains the number of reads for every pool 
#One contains the distribution (How many UIDs have a certain coverage) 
def read_file(filename, distribution_dict, number_of_reads): 
    pool_name = file.split("_")[1] 
 
    #gets the dictionary for the pool if it exits or creates a new one 
    if pool_name in distribution_dict: 
        pool_dict = distribution_dict[pool_name] 
    else: 
        pool_dict = {} 
    #to count the number of reads for this file 
    file_read_number = 0 
 
    #read the file 
    with open(distribution_folder + "/" + file) as f: 
        content = f.readlines() 
 
    #for every line in the file 
    for line in content: 
        #we get the uid and how often it occurs 
        unique_uid = line.strip().split("\t")[0] 
        num_of_occ = line.strip().split("\t")[1] 
        #the sum of occurences is the number of reads for this pool 
        #because every uid is unique 
        file_read_number += int(num_of_occ) 
        #at least 5 different UIDs exist 
        if len(content) > 5: 
            #then it is not a chance match and we want to use it 
            #we save the uid in a list with all uids which occured the same 
            #number of times 
            if num_of_occ in pool_dict: 
                pool_dict[num_of_occ].append(unique_uid) 
            else: 
                pool_dict[num_of_occ] = [unique_uid] 
    #update the dictionary 
    distribution_dict[pool_name] = pool_dict 
 
    #save number of reads for this pool 
    if pool_name in number_of_reads: 
        number_of_reads[pool_name] = number_of_reads[pool_name] + file_read_number 
    else: 
        number_of_reads[pool_name] = file_read_number 
    #return the values so we can use them later 
    return (distribution_dict, number_of_reads) 
 





#returns a dictionary containing the number of reads smaller 
#a given threshold 
def get_reads_smaller_threshold(dist_dict, threshold): 
    read_num = {} 
    for pool in dist_dict: 
        pool_dict = dist_dict[pool] 
        num_of_reads = 0 
        for num in pool_dict: 
            if int(num) < threshold: 
                #number of reads is the coverage times the number of UIDs 
                #which have this coverage 
                num_of_reads += (int(num)*len(pool_dict[num])) 
        read_num[pool] = num_of_reads 
    return read_num 
 
#for only one pool 
#returns the number of reads which are greater or equal a given 
#coverage threshold 
def get_reads_greater_eq_threshold(pool_dict, threshold): 
    num_of_reads = 0 
    for num in pool_dict: 
        if int(num) >= threshold: 
            #number of reads is the coverage times the number of UIDs 
            #which have this coverage 
            num_of_reads += (int(num)*len(pool_dict[num])) 
    return num_of_reads 
 
#function that returns the max coverage of the pool 
def get_max_coverage(pool_dict): 
    cov_list = [] 
    for cov in pool_dict: 
        cov_list.append(int(cov)) 
    return max(cov_list) 
 
#function that returns a threshold value for the different pools 
#so that approximatly the same percentage of reads in every pool 
#is regarded 
def read_percent_to_threshold(given_reads, dist_dict, percent, threshold_dictionary): 
    for pool in dist_dict: 
        pool_dict = dist_dict[pool] 
        max_cov = get_max_coverage(pool_dict) 
        #print "MAX cov for pool %s is %i" %(pool, max_cov) 
        num_reads = 0 
        all_reads = given_reads[pool] 
        for cov in range(1,max_cov): 
            num_reads = get_reads_greater_eq_threshold(pool_dict, cov) 
            new_percent = float(num_reads) / float(all_reads) * 100.0 
            if new_percent <= percent: 
                threshold_dictionary[pool] = cov 
                break 
    return threshold_dictionary 
 
################################################################################ 
#                                                                              # 
#                                                                              # 
#                                  Main Script                                 # 
#                                                                              # 





dist_dict = {} 
initial_read_num = {} 
 
for file in os.listdir(str(distribution_folder+"/")): 
    if file.endswith(".txt"): 
        #call our function so that we get a dictionary which contains a 
        #dictionary for every pool, containing the read distribution 
        #and a dictionary which knows how many reads are in the pool 
        dist_dict, initial_read_num = read_file(file, dist_dict, initial_read_num) 
 
#get overall number of reads for every pool, a threshold we will never reach is 
#choosen to get all reads 
read_num = get_reads_smaller_threshold(dist_dict, 100000) 
reads_smaller_three = get_reads_smaller_threshold(dist_dict, min_read_coverage) 
 





min_pool = "" 
min_percent = 100.0 
for pool in read_num: 
    percent_used = float(read_num[pool]) / given_reads[pool] * 100.0 
    percent_used_cov = (float(read_num[pool]) - float(reads_smaller_three[pool]) ) / 
given_reads[pool] * 100.0 
    if percent_used_cov < min_percent: 
        min_pool = pool 
        min_percent = percent_used_cov 
 
print "The min percent of reads used is %.2f%% in pool %s" %(min_percent, min_pool) 
 
threshold_dict = {} 
#get the best matching threshold for this percentage 
threshold_dict = read_percent_to_threshold(given_reads, dist_dict, min_percent, 
threshold_dict) 
threshold_dict[min_pool] = min_read_coverage 
 
#print the percentage and matching threshold for every pool 
for pool in threshold_dict: 
    pool_dict = dist_dict[pool] 
    reads_for_pool = get_reads_greater_eq_threshold(pool_dict, threshold_dict[pool]) 
    percent_reads = float(reads_for_pool) / float(given_reads[pool]) * 100.0 
    print "The min coverage for pool %s should be %i covering %.2f%% of reads" %(pool, 
threshold_dict[pool], percent_reads) 
    reads_for_pool = get_reads_greater_eq_threshold(pool_dict, threshold_dict[pool]-1) 
    percent_reads = float(reads_for_pool) / float(given_reads[pool]) * 100.0 
    print "The min coverage minus 1 for pool %s should be %i covering %.2f%% of reads" 
%(pool, threshold_dict[pool]-1, percent_reads) 
    reads_for_pool = get_reads_greater_eq_threshold(pool_dict, threshold_dict[pool]+1) 
    percent_reads = float(reads_for_pool) / float(given_reads[pool]) * 100.0 
    print "The min coverage plus 1 for pool %s should be %i covering %.2f%% of reads" 
%(pool, threshold_dict[pool]+1, percent_reads) 
 
 
#This is for the percentage table from the presenentation 
#read_percent_used = [20, 25, 30, 35, 40, 45, 50, 55, 60] 
#for p in read_percent_used: 
#    thres_dict = {} 
#    thres_dict = read_percent_to_threshold(given_reads, dist_dict, p, thres_dict) 
#    for pool in thres_dict: 
#        pool_dict = dist_dict[pool] 







#python variants.py --infile R_2015_11_10_13_38_01_user_SN2-355-NH_FlutCORE_PGM-pool-
2015-021_Auto_user_SN2-355-NH_FlutCORE_PGM-pool-2015-021_448.basecaller.bam --fileprefix 
pool_21 --primer_forward CACAGTTCACAGCAGTAGGTAAAGA --primer_reverse ACAAATGCGATAACACGTGC 




#                                                                              # 
#                                imports                                       # 
#                                                                              # 
################################################################################ 
 
#here all modules we need are imported 
 
#this means we tell python that we want to use a 
 
















#from io import StringIO 
 
from StringIO import StringIO 
 
from Bio import AlignIO 
 
from Bio.Align import AlignInfo 
 
from Bio.Align.Applications import MafftCommandline 
 
from collections import defaultdict 
 
################################################################################ 
#                                                                              # 
#                           commandline parameters                             # 
#                                                                              # 
################################################################################ 
 
parser = argparse.ArgumentParser(description='Processing ionTorrent reads from a bam 
file to get information about how often a virus variant occurs by creating consensus 








dest='fileprefix',help='Prefix used in intermediate filenames') # input gtf file 
 
parser.add_argument('--primer_forward', action='store', dest='primer_forward', type=str, 
required=True, help='A sequene which stands before the beginning of the regarded 
sequence.') 
 
parser.add_argument('--primer_reverse', action='store', dest='primer_reverse', type=str, 








#max_seq_length=300  #no longer needed 
 
parser.add_argument('--quality', action='store_true', default=False, help='If quality 
filterng using fastx tools should be used set this flag.') 
 
parser.add_argument('--quality_min', action='store', dest='quality_min',type=int, 
default=20, help='Min base quality to keep, default value is 20.') 
 
parser.add_argument('--quality_percent', action='store', 
dest='quality_percent',type=int, default=95, help='Percent of bases which should have 
min quality, default is 95 Percent.') 
 
parser.add_argument('--mask', action='store_true', default=False, help='If masking of 
bases below a minimum quality is required, set this flag.') 
 
parser.add_argument('--filter_length', action='store_true', dest='filter_length', 
default=False, help='If sequences below a certain length should be excluded, set this 
flag.') 
 
parser.add_argument('--min_seq_length', action='store', dest='min_seq_length', 
default=270, help='The min length a sequence needs to have.') 
 
parser.add_argument('--max_seq_length', action='store', dest='max_seq_length', 
default=500, help='The max length a sequence can to have.') 
 
parser.add_argument('--poly_A', action='store_true', dest='poly_A', default=False, 
help='If this flag is set a correction for the three known poly a stretches is 
performed.') 
 
#parser.add_argument('--fastq', action='store_true', default=False, help='fastq flies 






parser.add_argument('--uid_threshold', action='store', dest='uid_threshold', type=int, 
default=3, help='Minimum coverage a uid has to have.') 
 
parser.add_argument('--threshold_consens', action='store', dest='threshold_consens', 
help='A file containing the minimum number of sequences which have to be the same for 
the letter to be called in the consensus ssequence.') 
 
arguments = parser.parse_args() 
 
assert os.path.isfile(arguments.infile), "Bam input file not found '%s' " % 
arguments.infile 
 
#create folders to save the files 
 
main_folder = arguments.fileprefix + "/" 
 
if not os.path.exists(main_folder): 
 
    os.mkdir(main_folder) 
 
#all_files = main_folder + "intermediatefiles_"+ arguments.fileprefix + "/" 
 
#if not os.path.exists(all_files): 
 
#    os.mkdir(all_files) 
 
intermed = main_folder + "MIDS/" 
 
if not os.path.exists(intermed): 
 




results_folder = main_folder + "RESULTS/" 
 
if not os.path.exists(results_folder): 
 










print("                         Infile: %s" %(arguments.infile)) 
 
print("        Results can be found in: %s" %(results_folder)) 
 
print("   All in files can be found in: %s" %(main_folder)) 
 
print("             The file prefix is: %s" %(arguments.fileprefix)) 
 




    print("Filtering for qulatity using the parameters:") 
 
    print("                         Min quality to keep: %i" %(arguments.quality_min)) 
 



































    print("No change is performed on Poly A stretches.") 
 
print("A min number of %i seqences starting with the same UID is needed to consider the 









#                                                                              # 
#                                   functions                                  # 
#                                                                              # 
################################################################################ 
 
#needs the sequence and the matching score line 
 
#returns the sequence shortend to between primers 
 
def find_seq_between_primer(seq, score, forward, reverse): 
 
    res="" 
 
    primer_found=False 
 
    try: 
 
        primer_forward_index = seq.index(forward) 
 
        primer_found=True 
 
    except: 
 
        res="NA" 
 
    #gets the starting position of the reverse primer 
 
    try: 
 
        primer_reverse_index = seq.index(reverse) 
 
    except: 
 
        primer_found=False 
 
        res="NA" 
 
    if primer_found: 
 
        #the sequence becomes the sequence starting from the primer_forward 
 
        #assert(len(seq) == len(score)) 
 
        new_seq = seq[ (primer_forward_index + len(forward)) : primer_reverse_index ] 
 
        new_score = score[ (primer_forward_index + len(forward)) : primer_reverse_index 
] 
 






    return res 
 
#reads in the fastq file are sorted by MIDs 
 
#each MID is associated with a dictionary using UIDs as keys 
 
#every UID entry has a list with lists of the sequence entry 
 
def read_fastq(fastq_file_name, mid_dict): 
 
    counter = 0 
 
    for line in open(fastq_file_name): 
 
        counter += 1 
 
        #if it is a fastq file a read consitst of 4 lines 
 
        #if the counter is 1 the line is the sequence header 
 
        if counter == 1: 
 
            header_seq = line 
 
            #print header_seq.strip('\n') 
 
        #if the counter is 2 the line is the sequence 
 
        if counter == 2: 
 
            seq = line 
 
        #if the counter is 3 the line is the header of the score 
 
        if counter == 3: 
 
            header_score = line 
 
        #if the counter is 4 the line is the line of scores 
 
        #everything we want to do with the lines should be done in this step 
 
        if counter == 4: 
 
            score = line 
 
            counter=0 
 
            #take mid as first dict key 
 
            mid = seq[0:10] 
 
            uid = seq[10:24] 
 
            if mid in mid_dict: 
 
                dict_of_mid = mid_dict[mid] 
 
                if uid in dict_of_mid: 
 
                    uid_list = dict_of_mid[uid] 
 
                    uid_list.append([header_seq, seq, header_score, score]) 
 
                    dict_of_mid[uid] = uid_list 
 
                else: 
 
                    dict_of_mid[uid] = [[header_seq, seq, header_score, score]] 
 
                mid_dict[mid] = dict_of_mid 
 
    return mid_dict 
 
#this function filters for length of the sequences 
 






    new_mid_dict = {} 
 
    for mid in mid_dict: 
 
        m_dict = mid_dict[mid] 
 
        new_uid_dict = {} 
 
        for uid in m_dict: 
 
            #list of entries for this uid 
 
            u = m_dict[uid] 
 
            u_list = [] 
 
            for entry in u: 
 
                #if sequence is longer min and shorter max 
 
                if (len(entry[1]) > min_length) and (len(entry[1]) < max_length): 
 
                    #then add to the list 
 
                    u_list.append(entry) 
 
            #if sequences with this uid are left 
 
            if len(u_list) > 0: 
 
                new_uid_dict[uid] = u_list 
 
        new_mid_dict[mid] = new_uid_dict 
 
    return new_mid_dict 
 
#prints the uid and how often it occures in one file 
 
def creating_distribution_files(mid_dict, mid_to_seq): 
 
    for mid in mid_dict: 
 
        #folder = mid_folder[mid] 
 
        distribution_file = intermed + mid_to_seq[mid] + "_unique_uids.csv" 
 
        dist_file = open(distribution_file, 'w') 
 
        for uid in mid_dict[mid]: 
 
            cov = len(mid_dict[mid][uid]) 
 
            dist_file.write(uid + "," + str(cov) + "\n") 
 




    read_counter = 0 
 
    for mid in mid_dict: 
 
        for uid in mid_dict[mid]: 
 
            read_counter += len(mid_dict[mid][uid]) 
 




    read_num_dict = {} 
 
    for mid in mid_dict: 
 
        read_counter = 0 
 






            read_counter += len(mid_dict[mid][uid]) 
 
        read_num_dict[mid] = read_counter 
 
    return read_num_dict 
 
def correct_for_poly_A(mid_dict, mid_folder, mid_to_seq): 
 
    positions=[[60,73],[84,97],[218,231]] 
 
    ploy_A_seven="AAAAAAA" 
 
    new_mid_dict = {} 
 
    for mid in mid_dict: 
 
        modifications = mid_folder + mid_to_seq[mid] + "_poly_A_modifications.txt" 
 
        mod_file = open(modifications, 'w') 
 
        uid_dict = mid_dict[mid] 
 
        new_uid_dict = {} 
 
        for uid in uid_dict: 
 
            new_entry_list = [] 
 
            for entry in uid_dict[uid]: 
 
                #print "enty for uid %i " %(len(entry)) 
 
                new_entry = [entry[0],entry[1],entry[2],entry[3]] 
 
                ind = 0 
 
                seq = entry[1] 
 
                score = entry[3] 
 
                pos_to_delete = [] 
 
                for pos in positions: 
 
                    try: 
 
                        #if a ploy A stretch of seven or longer is detected the starting 
index is saved 
 
                        ind = seq.index(ploy_A_seven, pos[0], pos[1]) 
 
                        #in the list of positions which should be deleted 
 
                        pos_to_delete.append(ind+6) #because we want to delete the last 
A 
 
                        #and every A in the poly a stretch following the sixth A 
 
                        #the loop is performed as long as a is True 
 
                        a=True 
 
                        #index in the sequence of the seventh A 
 
                        i=ind+6 
 
                        while a: 
 
                            #the index in the string is counted up 
 
                            i+=1 
 
                            if (seq[i] == 'A'): 
 
                                #if it is A, the position needs to be deleted 
 






                                pos_to_delete.append(i) 
 
                            else: 
 
                                #the poly A stretch is over ass soon as the position 
 
                                #contains an other character than A, so a is set to 
 
                                #false which meens the loop is not performed any more 
 
                                a=False 
 
                    except: 
 
                        #everything is normal, the poly A stretch is not to long 
 
                        ind = 0 
 
                if pos_to_delete != []: 
 
                    #reverse the order so that the highest position is deleted first and 
 
                    #no problems with a moving index is created 
 
                    for i in reversed(pos_to_delete): 
 
                        assert(len(seq) == len(score)) 
 
                        #remove according to index 
 
                        #largest index is removed first 
 
                        #because the seq and the score lines have the same length 
 
                        #the position is deleted from both 
 
                        if(i < len(seq)): 
 
                            phred=str(ord(score[i])-33) 
 
                            mod = entry[0].strip("\n") + "\t" + seq[1:24] + "\t" + 
seq[i] + "\t" + phred + "\n" 
 
                            #print mod 
 
                            mod_file.write(mod) 
 
                            seq = seq[:i] + seq[i+1:] 
 
                            score = score[:i] + score[i+1:] 
 
                            new_entry = [entry[0], seq, entry[2], score] 
 
                            #print "Corrected for a poly A stretch" 
 
                new_entry_list.append(new_entry) 
 
            new_uid_dict[uid] = new_entry_list 
 
            #print "new entry length %i " %(len(new_entry_list)) 
 
        new_mid_dict[mid] = new_uid_dict 
 
        #print "length mid dict %i " %(len(new_mid_dict)) 
 
        mod_file.close() 
 
    return new_mid_dict 
 
def read_consensus_threshold_file(threshold_file, threshold_dict): 
 
    for line in open(threshold_file): 
 
        content = line.strip().split('\t') 
 






        percentage = content[1] 
 
        percentage = percentage.replace(',','.') 
 
 threshold_dict[coverage] = percentage 
 
    return threshold_dict 
 
def create_align(fasta_file_name, uid_reads, threshold_dict): 
 
    number_of_reads = 0 
 
    new_fasta = open(fasta_file_name, 'w') 
 
    for entry in uid_reads: 
 
        number_of_reads +=1 
 
        header = entry[0].strip() 
 
        sequence = entry[1].strip() 
 
        new_fasta.write(">" + header[1:] + "\n" + sequence + "\n") 
 
    new_fasta.close() 
 
    #the alighnment is created using mafft 
 
    mafft_cline = MafftCommandline(input=fasta_file_name) 
 
    stdout, stderr = mafft_cline() 
 
    #here the alighnment is read from the mafft output 
 
    align = AlignIO.read(StringIO(stdout), "fasta") 
 
    #get the consensus sequence from the alignment 
 
    summary_align = AlignInfo.SummaryInfo(align) 
 
    threshold_consens = threshold_dict[str(number_of_reads)] 
 
    float_thres = float(threshold_consens) / 100.0 
 
    consensus = summary_align.gap_consensus(ambiguous="N", threshold=(float_thres-0.1)) 
 
    #starts from end of primer_forward to beginning of primer_reverse 
 
    #immediatley use consensus sequence without gaps 
 
    #table = {ord('-') : None} 
 
    #consensus_without_gap = str(consensus).translate(table) 
 
    consensus_without_gap = str(consensus).translate(None, '-') 
 
    return [header, consensus_without_gap] 
 
def count_consensus_seq(consens_dict, result_file): 
 
    num_sequences = len(consens_dict) 
 
    count = dict() 
 
    for consensus in consens_dict: 
 
        consensus_seq = consens_dict[consensus][0] 
 
        num_of_reads = consens_dict[consensus][1] 
 
        if consensus_seq in count: 
 
            count[consensus_seq][0] += 1 
 
            count[consensus_seq][1] += num_of_reads 
 






            count[consensus_seq] = [1 , num_of_reads] 
 
    stats = open(result_file, 'w') 
 
    for seq in count: 
 
        p = float(count[seq][0])/float(num_sequences) 
 
        line = "%s,%i,%.3f,%i\n" %(seq, count[seq][0], p, count[seq][1] ) 
 
        #line = seq + ',' + str(count[seq]) + ',' + 
str(float(count[seq])/float(num_sequences) + "\n") 
 
        stats.write(line) 
 
    stats.close() 
 
################################################################################ 
#                                                                              # 
#                                   analysis                                   # 
#                                                                              # 
################################################################################ 
 
#read in individual threshold 
 
threshold_dict = {} 
 
threshold_dict = read_consensus_threshold_file(arguments.threshold_consens, 
threshold_dict) 
 
#mid_to_seq = {"CGAGGTTATC":"MID30"  } 
 
mid_to_seq = {"TTCGTGATTC":"MID07" , "TCCTCGAATC":"MID11" , "TTAGTCGGAC":"MID19" , 
"CGAGGTTATC":"MID30" } 
 
#mid_to_seq = {"TTCGTGATTC":"MID07"} 
 
#mid_seq = ["TTCGTGATTC", "TCCTCGAATC", "TTAGTCGGAC", "CGAGGTTATC" ] 
 
#mids = ["MID07", "MID11", "MID19", "MID30"] 
 




mid_folder = {} 
 
for mid in mid_to_seq: 
 
    mid_folder_name = intermed + mid_to_seq[mid] + "/" 
 
    if not os.path.exists(mid_folder_name): 
 
        os.mkdir(mid_folder_name) 
 
    mid_folder[mid] = mid_folder_name 
 
#convert the bam file to a fastq file 
 
fastq_file_name = main_folder + arguments.fileprefix + ".fastq" 
 
#bam_call = "samtools fastq %s" %(arguments.infile) 
 
bam_call = "bam2fastx -q %s" %(arguments.infile) 
 
args = shlex.split(bam_call) 
 
fastq_file = open(fastq_file_name, "w+") 
 






#for read counting 
 






#read_num = count_reads(mid_dict_for_counting) 
 




    print("Filtering for quality:") 
 
    print("%i%% of bases need to have min quality score of %i." 
%(arguments.quality_percent, arguments.quality_min)) 
 
    qualtity_file = "%s%s_quality_filterd_%i_%i.fastq" %(main_folder, 
arguments.fileprefix, arguments.quality_min, arguments.quality_percent) 
 
    quality_line = "fastq_quality_filter -q %i -p %i -i %s -o %s" 
%(arguments.quality_min, arguments.quality_percent, fastq_file_name, qualtity_file) 
 
    args = shlex.split(quality_line) 
 
    p = subprocess.Popen(args) 
 
    p.wait() 
 
    fastq_file_name = qualtity_file 
 
    #mid_dict_for_counting = read_fastq(fastq_file_name, mid_dict) 
 
    #read_num = count_reads(mid_dict_for_counting) 
 




    print("Masking bases below a qualtiy score of %i" %(arguments.quality_min)) 
 
    #mask all nucleotides with N wich have a quality smaller the min_quality 
 
    masked_file = "%s%s_masked_below_%i.fastq" %(main_folder, arguments.fileprefix, 
arguments.quality_min) 
 
    mask_line = "fastq_masker -q %i -i %s -o %s" %(arguments.quality_min, 
fastq_file_name, masked_file) 
 
    args = shlex.split(mask_line) 
 
    p = subprocess.Popen(args) 
 
    p.wait() 
 
    fastq_file_name = masked_file 
 
    #mid_dict_for_counting = read_fastq(fastq_file_name, mid_dict) 
 
    #read_num = count_reads(mid_dict_for_counting) 
 
    #print("+++++++ Number of Reads after masking %i" %(read_num)) 
 




mid_dict = read_fastq(fastq_file_name, mid_dict) 
 
print("Num of MIDs %i" %(len(mid_dict))) 
 
read_num = count_reads(mid_dict) 
 
print("+++++++ Number of Reads for processing %i" %(read_num)) 
 
read_num_dict = count_reads_per_mid(mid_dict) 
 
for mid in read_num_dict: 
 
    print("%s Num of UIDs %i" %(mid_to_seq[mid],len(mid_dict[mid]))) 
 








    print("Filter reads for length.") 
 
    mid_dict = filter_for_length(mid_dict, arguments.min_seq_length, 
arguments.max_seq_length) 
 
    read_num = count_reads(mid_dict) 
 
    print("+++++++ Number of Reads after length filter %i" %(read_num)) 
 
    read_num_dict = count_reads_per_mid(mid_dict) 
 
    for mid in read_num_dict: 
 
        print("%s Num of UIDs %i" %(mid_to_seq[mid],len(mid_dict[mid]))) 
 




    print("Correcting Poly A stretches") 
 
    mid_dict = correct_for_poly_A(mid_dict, intermed, mid_to_seq) 
 
    read_num = count_reads(mid_dict) 
 
    print("+++++++ Number of Reads after poly A correction %i" %(read_num)) 
 
    read_num_dict = count_reads_per_mid(mid_dict) 
 
    for mid in read_num_dict: 
 
        print("%s Num of UIDs %i" %(mid_to_seq[mid],len(mid_dict[mid]))) 
 
        print("+++++++ %s has %i reads" %(mid_to_seq[mid], read_num_dict[mid])) 
 
print("Searching for the sequences between primers") 
 
for mid in mid_dict: 
 
    m_dict = mid_dict[mid] 
 
    new_uid_dict = {} 
 
    for uid in m_dict: 
 
        #new list of entries for this uid 
 
        u_list = [] 
 
        #print len(m_dict[uid]) 
 
        count = 0 
 
        for entry in m_dict[uid]: 
 
            #print "entry" 
 
            #print entry 
 
            #[seq, score] 
 
            count += 1 
 
            #print "Searching for seq %i %i" %(count, len(entry)) 
 
            res = find_seq_between_primer(entry[1], entry[3], arguments.primer_forward, 
arguments.primer_reverse) 
 
            if res != "NA": 
 
                new_entry = [entry[0], res[0], entry[2], res[1]] 
 
                u_list.append(new_entry) 
 






            new_uid_dict[uid] = u_list 
 




read_num = count_reads(mid_dict) 
 
print("+++++++ Number of Reads after primer filtering %i" %(read_num)) 
 
read_num_dict = count_reads_per_mid(mid_dict) 
 
for mid in read_num_dict: 
 
    print("%s Num of UIDs %i" %(mid_to_seq[mid],len(mid_dict[mid]))) 
 
    print("+++++++ %s has %i reads" %(mid_to_seq[mid], read_num_dict[mid])) 
 






print("Creating a file for every UID with a coverage greater %i and creating a consensus 
sequence" %(arguments.uid_threshold)) 
 
#go over all mids seperatly 
 
used_reads = 0 
 
for mid in mid_dict: 
 
    used_reads_mid = 0 
 
    print("currently on MID %s" %(mid)) 
 
    result_file = results_folder + arguments.fileprefix + "_" + mid_to_seq[mid] + 
"_stats.csv" 
 
    consensus_file = intermed + arguments.fileprefix + "_" + mid_to_seq[mid] + 
"_consensus.fa" 
 
    consensus_seq = open(consensus_file, 'w') 
 
    consens_dict = {} 
 
    #results_files[mid] = result_file 
 
    for uid in mid_dict[mid]: 
 
        #print(uid) 
 
        new_uid_fasta = mid_folder[mid] + uid + "_seq_between_primer.fa" 
 
        uid_enties = mid_dict[mid][uid] 
 
        if len(uid_enties) >= arguments.uid_threshold: 
 
            used_reads += len(uid_enties) 
 
            used_reads_mid += len(uid_enties) 
 
            consens = create_align(new_uid_fasta, uid_enties, threshold_dict) 
 
            consens_header = consens[0] + "occured: " + str(len(uid_enties)) 
 
            consens_seq = consens[1] 
 
            #starts from end of primer_forward to beginning of primer_reverse 
 
            #immediatley use consensus sequence without gaps 
 
            consensus_seq.write(consens_header + "\n" + consens_seq + "\n") 
 
            consens_dict[consens_header] = [consens_seq, len(uid_enties)] 
 






    print("Create the statistic results for mid %s" %(mid_to_seq[mid])) 
 
    count_consensus_seq(consens_dict, result_file) 
 
    consensus_seq.close() 
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